DOCSLIB.ORG

1: Gastro-Intestinal System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1: Gastro-Intestinal System © palliativedrugs.com Ltd. 1: GASTRO-INTESTINAL SYSTEM Antacids ........................................................ 1 Lactulose.................................................. 32 Alginate products ..................................... 2 Polyethylene glycol (macrogol) .......... 33 Simethicone................................................ 3 Magnesium salts ..................................... 34 Antimuscarinics ........................................ 5 Rectal products ...................................... 35 Hyoscine (scopolamine) Products for hemorrhoids ................ 37 butylbromide ........................................... 11 Pancreatin .................................................38 Prokinetics ................................................ 13 H 2 -receptor antagonists ..................... 15 Guidelines: Management of Misoprostol ............................................... 18 death rattle (noisy respiratory Proton pump inhibitors ...................... 19 secretions) .................................................10 Loperamide .............................................. 22 Guidelines: Opioid-induced Laxatives .................................................... 24 constipation .............................................. 26 Psyllium husk .......................................... 28 Guidelines: Bowel management Contact (stimulant) laxatives .............. 29 in paraplegia and tetraplegia ........... 27 Docusate sodium ................................... 31 ANTACIDS Antacids taken by mouth to neutralize gastric acid include: . magnesium salts . aluminum hydroxide . calcium carbonate . sodium bicarbonate. Magnesiumsalts are laxative and can cause diarrhea; aluminum salts constipate. Most proprietary antacids contain amixtureof magnesium salts and aluminum salts so as to have aneutral impact on intestinal transit. With doses of 4 100–200mL/24h, the effect of magnesium salts tends increasingly to override the constipating effect of aluminum. 1 The sodium content of some antacids maybedetrimental in patients on salt-restricted diets, e.g. those with hypertension or heart failure; Gaviscon. R Liquid (available OTC) contains Naþ 53mg/5mL (equivalentto4.6mmol/10mL dose) compared with 0.1nmol/10mL in aluminum hydroxide- magnesium hydroxide suspension (e.g. Almagel. R ). Regular use of sodium bicarbonate maycause sodium loading and metabolicalkalosis. Calcium carbonate maycause rebound acid secretion about 2h after each dose, and regular use maycause hypercalcemia, particularly if taken with sodium bicarbonate. Aluminum hydroxide binds dietaryphosphate.Itisofbenefit in patients with hyper- phosphatemiainrenal failure. Long-term complications of phosphate depletion and osteomalacia are not an issue in advanced cancer. In post-radiation esophagitisand candidosis which is causing painful swallowing, an aluminum hydroxide- magnesium hydroxide suspensioncontaining oxethazine,alocal anesthetic, can be helpful. Give5–10mL (without fluid) 15min a.c. &atbedtime, and p.r.n. beforedrinks. This should be regarded as short-term symptomatic treatment while time and specific treatment of the underlying condition permits healing of the damaged mucosa. Alternatively, lidocaine viscous oral suspension 2% (or acompounded lidocaine suspension) can be used (see p.449). The following should be borne in mind: . the administration of antacids should be separated from the administration of EC tablets; direct contact between EC tablets and antacids mayresult in damage to the enteric coating with consequential exposureofthe drug to gastric acid, and of the stomach mucosa to the drug . except for sodium bicarbonate,antacids delaygastric emptying and maythereby modify drug absorption. CPCF 1 © palliativedrugs.com Ltd. © palliativedrugs.com Ltd. ALGINATE PRODUCTS . most antacid tablets feel gritty when sucked; some patients dislikethis . R . some proprietaryproducts are fruit-flavoured, e.g. Tu ms (chewable tablet) . R . the cheapest single-ingredient product is aluminum hydroxide chewable tablets (Amphojel ) . the cheapestsingle-ingredient magnesium product is milk of magnesia liquid (generic), containing magnesium hydroxide 80mg/mL . the cheapest aluminum- magnesium combinationproduct is ageneric storebrand liquid product . some antacids contain additional substances for use in specific situations, e.g. alginates (see below), simethicone (see p.3) . magnesium-containing antacids should be used with caution in patients with renal impairment (see p.491); calcium carbonate is preferable. Antacids are now generally only used p.r.n. for occasionaldyspepsia; H 2 -receptor antagonists (see p.15) and PPIs (see p.19) are used when continuous gastric acid reduction is indicated.2 Supply See also Simethicone ,p.3. Aluminum hydroxide Amphojel. R (Aurium Pharma) Tablets chewable 600mg, 28 days @1t.i.d. &atbedtime ¼ $27; mint flavour. Oral suspension (sugar-free) 320mg/5mL,28days@10mL t.i.d. &atbedtime ¼ $38; mint flavour. Aluminum hydroxide- magnesium hydroxide Almagel 200. R (Laboratoire Atlas) Oral suspension (sugar-free) aluminum hydroxide 200mg, magnesium hydroxide 200mg/ 5mL, 28 days @10mL t.i.d. &atbedtime ¼ $13; low Naþ . Calcium carbonate Tu ms. R (GlaxoSmithKline) Tablets chewable regular strength, 500mg; extra strength, 750mg; ultra strength, 1,000mg; 28 days @2t.i.d. &atbedtime ¼ $7, $13 and $19 respectively; low Naþ ,fruit flavour. With oxethazine Mucaine. R suspension (Aurium Pharma) Oral suspension aluminum hydroxide 300mg, magnesium hydroxide 100mg, oxethazine 10mg/5mL,28days@10mL t.i.d. a.c. &atbedtime ¼ $77. 1Morrissey Jand Barreras R(1974) Antacid therapy. New England Journal of Medicine. 290:550–554. 2NICE (2004) Dyspepsia. Management of dyspepsia in adults in primarycare. In: Clinical Guideline 17.National Institute for Clinical Excellence. Available from: www.nice.org.uk/page.aspx?o¼ CG017 ALGINATE PRODUCTS Included for general information. Alginate products are generally not recommended as antacids for palliativecarepatients. Class: Alginate. Indications: Acid reflux (‘heartburn’). Pharmacology Antacid products containing alginic acid or sodium alginate preventesophageal reflux pain by forming an inert low-densityraft on the top of the acidic stomach contents. Both acid and air bubbles are necessarytoproduce the raft. Compoundalginate products maythus be less effective if used with drugs which reduce acid (e.g. an H 2 -receptor antagonist or aPPI) or products which reduce air bubbles (i.e. an antifoaming agent/antiflatulent). 2www.palliativedrugs.com © palliativedrugs.com Ltd. © palliativedrugs.com Ltd. SIMETHICONE Gaviscon. R Liquid, asodium alginate product, is aweak antacid; most of the antacid content adheres to the alginate raft. This neutralizes acid which seeps into the esophagus around the raft but does nothing to correct the underlying causes, e.g. lax lower esophagealsphincter, hyperacidity,delayed gastric emptying, obesity.Indeed, alginate-containing products arenobetter than simethicone-containing antacids in the treatment of acid reflux.1 Compound alginate products have been largely superseded by acid suppression with PPIs and H 2 -receptor antagonists. Onset of action 5 5min. Duration of action 1–2h. Cautions Gaviscon. R Liquid contains Naþ 53mg/5mL (equivalentto4.6mmol/10mL dose). It should not be used in patients requiring asalt-restricted diet, e.g. those with fluid retention, heart failureor renal impairment. Dose and use Several products are available but none is recommended.For patients already taking an alginate product and who are reluctant to change to aluminum hydroxide– magnesium hydroxide (or similar option), and if thereare grounds for limiting sodium intake, choose one with alow sodium content, e.g. Gaviscon Heartburn Relief Tablets. R (22mg Naþ /tablet). Supply Gaviscon. R Liquid and tablets are available OTC. Gaviscon Liquid. R (GlaxoSmithKline) Oral suspension (sugar-free) sodium alginate 250mg, aluminum hydroxide 100mg/5mL, 340mL bottle ¼ $13 and 600mL bottle ¼ $20; 53mg Naþ /5mL. Gaviscon Heartburn Relief Tablets. R (GlaxoSmithKline) Tablets chewable alginic acid 200mg, magnesium carbonate 40mg, 100 tablets ¼ $20; 22mg Naþ /tablet. Gaviscon Heartburn Relief Extra Strength Tablets. R (GlaxoSmithKline) Tablets chewable alginic acid 313mg, magnesium carbonate 63mg, 60 tablets ¼ $20; 35mg Naþ /tablet. MaaloxNighttime. R (Novartis) Oral suspension sodium alginate 275mg, calcium carbonate 300mg, magnesium carbonate 125mg/5mL,350mL bottle ¼ $12; 45mg Na/ 5mL, mint flavour. 1PokornyCet al. (1985) Comparison of an antacid/dimethiconemixture and an alginate/antacid mixture in the treatment of oesophagitis. Gut. 26:A574. SIMETHICONE Class: Antifoaming agent (antiflatulent). Indications: Acid dyspepsia (including acid reflux), gassy dyspepsia, † hiccup (if associated with gastric distension). Pharmacology Simethicone(silica-activated dimethicone or dimethylpolysiloxane) is amixtureofliquid dimethicones with silicon dioxide. It is an antifoaming agent present in several single-agent products (e.g. Ovol. R )and some combinationantacids (e.g. Diovol Plus. R and Maaloxantacid with anti-gas. R ). By facilitating belching, simethicone eases flatulence, distension and postprandial gastric discomfort. Simethicone-containing antacids are as effectiveasalginate-containing CPCF 3 © palliativedrugs.com Ltd. © palliativedrugs.com Ltd. SIMETHICONE products in the treatment of acid reflux.1 Simethicone-containing antacids should be used in preferenceto alginate products because they are moreeffectiveantacids, are cheaper,and
Load more

Recommended publications
  • Chemicals Used for Chemical Manufacturing Page 1 of 2
    Chemicals used for Chemical Manufacturing Page 1 of 2 Acetic Acid (Glacial, 56%) Glycol Ether PMA Acetone Glycol Ether PNB Acrylic Acid Glycol Ether PNP Activated Carbon Glycol Ether TPM Adipic Acid Glycols Aloe Vera Grease Aluminum Stearate Gum Arabic Aluminum Sulfate Heat Transfer Fluids Amino Acid Heptane Ammonium Acetate Hexane Ammonium Bicarbonate Hydrazine Hydrate Ammonium Bifluoride Hydrochloric Acid (Muriatic) Ammonium Chloride Hydrogen Peroxide Ammonium Citrate Hydroquinone Ammonium Hydroxide Hydroxylamine Sulfate Ammonium Laureth Sulfate Ice Melter Ammonium Lauryl Sulfate Imidazole Ammonium Nitrate Isobutyl Acetate Ammonium Persulfate Isobutyl Alcohol Ammonium Silicofluoride Calcium Stearate Dipropylene Glycol Isopropanolamine Ammonium Sulfate Carboxymethylcellulose Disodium Phosphate Isopropyl Acetate Antifoams Caustic Potash D'Limonene Isopropyl Alcohol Antifreeze Caustic Soda (All Grades) Dodecylbenzene Sulfonic Acid Isopropyl Myristate Antimicrobials Caustic Soda (Beads, Prills) (DDBSA) Isopropyl Palmitate Antimony Oxide Cetyl Alcohol Dowfrost Itaconic Acid Aqua Ammonia Cetyl Palmitate Dowfrost HD Jojoba Oil Ascorbic Acid Chlorine, Granular Dowtherm SR-1 Keratin Barium Carbonate Chloroform Dowtherm 4000 Lactic Acid Barium Chloride Chromic Acid EDTA Lanolin Beeswax Citric Acid (Dry and Liquid) EDTA Plus Lauric Acid Bentonite Coal Epsom Salt Lauryl Alcohol Benzaldehyde Cocamide DEA Ethyl Acetate Lecithin Benzoic Acid Copper Nitrate Ethyl Alcohol (Denatured) Lime Benzyl Alcohol Copper Sulfate Ethylene Glycol Linoleic Acid Bicarbonate
    [Show full text]
  • Purified Sea Salt with Magnesium Carbonate
    Cargill® Food Processing Salts Purified Sea Saltwith Magnesium Carbonate Product Description Physical Information Purified Sea Salt with Magnesium Carbonate This material is a food grade, granular, white crystalline Purified Sea Salt with Magnesium Carbonate sodium chloride product manufactured under stringent PHYSICAL MIN TARGET MAX process control procedures. Cargill Sea Salts are made from Pacific Ocean sea salt, which is harvested from ponds NaCl (%) 99.7 99.96 100 near the San Francisco Bay. Ca & Mg as Ca (%) 0.003 Sulfate as SO4 (%) 0.01 Product Application Water Insolubles (%) 0.025 0.01 Bulk Density (#cu/ft) 69 74 84 This material is intended for table and cooking use, as well as direct application in foods manufactured by the various Bulk Density (g/l) 1105 1185 1345 food processing industries. This material contains Surface Moisture (%) 0.02 Magnesium Carbonate, which is added to improve caking Magnesium Carbonate (%) 0.5 resistance and flowability. PERCENT PARTICLE SIZE MIN TARGET MAX Product Certifications DISTRIBUTION (SCREENS) Sieve - USS 30 Mesh Retained 0 40 50 Cargill® Sea Salts meet USDA, FDA and Food Chemicals Codex for food use. Sieve - USS 40 Mesh Retained 34 Sieve - USS 50 Mesh Retained 16 Cargill® Sea Salts are certified Kosher for Passover (OU-P) SieveCargill - USS 70 Mesh® RetainedSea Salt 8 by the Orthodox Union. Sieve - Retained on Pan 0 1 10 Made with Sun, Wind and Time Allergen Status Harvesting sea salt from San Francisco Bay today is similar to the salt-making process that has been used for centuries. In accordance with the 2004 USA Food Allergen Labeling and Consumer Protection Act (FALCPA), no allergen declarations are required for this product.
    [Show full text]
  • The Comparison of the Effect Between Alginate-Based Raft-Forming Liquid and Alginate Liquid on Gastroesophageal Reflux Disease and Gastric Ulcer in Rats
    Online - 2455-3891 Vol 10, Issue 12, 2017 Print - 0974-2441 Research Article THE COMPARISON OF THE EFFECT BETWEEN ALGINATE-BASED RAFT-FORMING LIQUID AND ALGINATE LIQUID ON GASTROESOPHAGEAL REFLUX DISEASE AND GASTRIC ULCER IN RATS HAKIM BANGUN1*, ANAYANTI ARIANTO1, RIRIN ASTYA1, GONTAR A SIREGAR2 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Nanomedicine Center, University of Sumatera Utara, Jl. Tri Dharma No. 5, Kampus USU, Medan, Indonesia. 2Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Jl Dr. T. Mansyur No. 5, Kampus USU, Medan, Indonesia. Email: [email protected] Received: 04 July 2017, Revised and Accepted: 16 August 2017 ABSTRACT Objective: The objective of the study was to compare the effect between alginate (Alg)-based raft-forming and Alg liquid on healing gastroesophageal reflux disease (GERD) and gastric ulcer in rats. Methods: Each of the 18 fasted rats was given 1 ml acidified pepsin. Then, rats were divided into three groups. Each group consisted of six rats. Group 1 (negative control) was orally given 1 ml distilled water, Group 2 was given 1 ml Alg-based raft-forming liquid, and Group 3 was given 1 ml Alg liquid. Then, the abdomen of rats was incised under anesthesia with ketamine, and then both their pylorus and the forestomach were ligated to form gastric reflux. After 4 hrs, all rats were killed with chloroform and their esophagus and stomach were examined macroscopically and microscopically (histopathology). Results: On macroscopic observation, all of the Group 1 rats (negative control) showed esophageal lesions and gastric lesions. Four rats of Group 2 (given Alg-based raft-forming) showed no esophageal lesion and two more rats showed a slight lesion, but all of the tested rats showed gastric lesions.
    [Show full text]
  • RAFT FORMING SYSTEM a REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Journal of Drug Delivery and Therapeutics (JDDT) Bhavsar et al Journal of Drug Delivery & Therapeutics; 2012, 2(5), 123-128 123 Available online at http://jddtonline.info REVIEW ARTICLE ADVANCES IN GRDDS: RAFT FORMING SYSTEM A REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C. Sini Surendran, Shah Viral H, Upadhyay UM Dept. of pharmaceutics, Sigma Institute of Pharmacy, Bakrol, Vadodara(Gujarat), India *Corresponding Author’s Ph: +91-9725512814, Email id: [email protected] Received 06 June 2012; Review Completed 26 Aug 2012; Accepted 26 Aug 2012, Available online 15 Sep 2012 ABSTRACT: In recent years several advancements has been made in research and development of Gastro retentive drug delivery system to overcome the drawback of non-site specificity when drug administered orally. In order to understand various physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention time. We have reviewed various gastro retentive approaches designed and developed until now i.e. floating drug dosage systems (FDDS), swelling or expanding systems, mucoadhesive systems, high density system, Raft forming system, magnetic systems. Among these systems, the review summarizes the special focus on raft forming approach which comes under floating drug delivery system. Raft system incorporates alginate gels which have carbonate components react with gastric acid causes bubbles and this enables floating. Finally, Evaluation, advantages, disadvantages, future potential and marketed preparation of raft forming approach in gastro retentive drug delivery systems were covered. Key words-Advances in GRDDS, Raft forming system, alginic acid, gaviscon, INTRODUCTION: Conventional oral delivery is widely used in 4) Drugs with a narrow window of absorption E.g.
    [Show full text]
  • Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
    0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • Medication Other Information Aches and Pains Constipation Cough/Cold Diarrhea Fever Over the Counter Medications in Pregnancy
    Over the Counter Medications in Pregnancy Women commonly use over the counter medications in pregnancy. This is a list of those medication you may safely use during pregnancy. If you have any questions about these medications and how to use them please contact your Healthcare Provider's office. Unless otherwise stated please take the medication as directed on the manufactures label. Medication Other Information Aches and Pains * Tylenol Extra Strength 500 mg tablet No more than 6 tablets in a 24 hour period * Tylenol 325 mg tablet No more than 8 in a 24 hour period Constipation Stool Softener Increases the amount of water in your stools to make them easier to pass * Colace (docusate sodium) * Surfak (docusate calcium) * Docusate Fiber Laxative Increases the amount of bulk in your stools to make them easier to pass * Metamucil (psyllium) * Fibercon (Calcium polycarbophil 625 mg) Stool Softener/Fiber Laxative Increases the amount of water in your stools to make them easier to pass * Peri-Colace (docusate sodium/sennosides) * Senekot -S (docusate sodium/sennosides) Osmotic Laxative Increases the amount of water in your stools to make them easier to pass * Milk of Magnesia * MiraLax (polyethylene glycol 3350) Cough/Cold Expectorants Help thin mucus and phlegm so they can be coughed up * Robitussin * Guaifenesin Antihistamines Can be used to relieve seasonal allergy and common cold symptoms of nasal congestion, * Chlorpheniramine sneezing and itchy eyes Cough Suppressants Help calm a cough * Dextromethorphan Decongestants Are used to relieve
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
    [Show full text]
  • Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology
    nanomaterials Article Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology Georg Gravogl 1,2, Christian Knoll 2,3 , Jan M. Welch 4, Werner Artner 5, Norbert Freiberger 6, Roland Nilica 6, Elisabeth Eitenberger 7, Gernot Friedbacher 7, Michael Harasek 3 , Andreas Werner 8, Klaudia Hradil 5, Herwig Peterlik 9, Peter Weinberger 2 , Danny Müller 2,* and Ronald Miletich 1 1 Department of Mineralogy and Crystallography, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (G.G.); [email protected] (R.M.) 2 Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (C.K.); [email protected] (P.W.) 3 Institute of Chemical, Environmental & Biological Engineering, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 4 Atominstitut, TU Wien, Stadionallee 2, 1020 Vienna, Austria; [email protected] 5 X-ray Center, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (W.A.); [email protected] (K.H.) 6 RHI-AG, Magnesitstraße 2, 8700 Leoben, Austria; [email protected] (N.F.); [email protected] (R.N.) 7 Institute of Chemical Technologies and Analytics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (E.E); [email protected] (G.F.) 8 Institute for Energy Systems and Thermodynamics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 9 Faculty of Physics, University of Vienna, Boltzmanngasse 5, 1090 Vienna, Austria; [email protected] * Correspondence: [email protected]; Tel.: +43-1-5880-1163-740 Received: 31 August 2018; Accepted: 2 October 2018; Published: 7 October 2018 Abstract: Thermochemical energy storage is considered as an auspicious method for the recycling of medium-temperature waste heat.
    [Show full text]
  • Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization
    Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization Darren Pasay, B.Sc.Pharm Drug Stewardship Pharmacist (Central Zone) [email protected] Disclosure I have no actual or potential conflict of interest in relation to this topic or presentation. Drug Stewardship in Alberta Health Services • Drug Stewardship (DS) Team established in 2012 • “The shared responsibility of Drugs & Safety Therapeutics Committee (DTC), prescribers, pharmacy and care units to ensure Sustainability medications are used in a manner that maximizes the effectiveness, safety and sustainability of care for our patients” Effectiveness • Research and project support Drugs & Therapeutics Backgrounders (DTBs) • Frontline staff wanted background and support on DTC/formulary issues1 • One page document, meant to enhance conversations with prescribers • Supported by content experts, based upon DTC directions • Published 6 times/year • Followed by 2 interactive webinars for each edition 1. Pasay Darren K, Chow Sheldon JS, Bresee Lauren C, Guirguis Micheal, Slobodan Jeremy. Assessment of current antimicrobial stewardship policies and resources: a focus group project. Healthcare Infection 2015; 20: 7–15. Docusate • Over-the-counter stool softener • It is clear, based on published peer-reviewed literature, that docusate is ineffective for the prevention or treatment of constipation • Open listed on AHS Provincial Drug Formulary • Limited coverage on Alberta Drug Benefit List (palliative care only) Docusate DTB • Preliminary work o ~ 2 million doses/year dispensed • Influences o Some LTC sites have eliminated o Engrained in practice use already • Part of pharmacy, medicine, nursing curriculums • Order sets, Pre-printed care • What are the costs of? orders (PPCO) o Procurement o Seen as innocuous, safe o Processing, dispensing o Medication administration o Medication burden BOTTOM LINE: Docusate is no more effective than placebo for the prevention and treatment of constipation.
    [Show full text]
  • United States Patent Office Patented Nov
    3,539,306 United States Patent Office Patented Nov. 10, 1970 2 properties of quick activity, durable effect and storage 3,539,306 PROCESS FOR THE PREPARATION Stability, and that, therefore, the same can provide an ex OF HYDROTALCITE cellent, ideal antacid. Teruhiko Kumura and Norio Imataki, Takamatsu-shi, Hydrotalcite is known as a mineral having a chemical Katuyuki Hasui, Kagawa-ken, and Takeo Inoue and 5 Structure of the formula Kimiaki Yasutomi, Nagao-machi, Kagawa-ken, Japan, assignors to Kyowa Chemical Industry Co., Ltd., Tokyo, MgAl(OH) 16CO3 4HO O Al2O3 6MgO CO2: 12H2O Japan, a corporation of Japan No Drawing. Filed July 21, 1967, Ser. No. 654,977 which has been naturally produced in only very limited Claims priority, application Japan, July 25, 1966, areas as Norway and Ural. Also a process for the syn 41/48,349; July 17, 1967, 42/45,658 O thesis of hydrotalcite was disclosed, which comprises add Int. C. COf 5/00, 7/00, A61k 27/06 ing Dry Ice or ammonium carbonate to a mixture of U.S. C. 23-315 4 Claims magnesium oxide and y-alumina or the thermal decom position product from of magnesium nitrate and aluminum nitrate, and thereafter maintaining the system at tempera ABSTRACT OF THE DISCLOSURE, tures below 325 C. and under elevated pressures of total A process for the preparation of hydrotalcite which 2,000-20,000 p.s.i. (Roy et al.: American Journal of comprises mixing an alumium component such as alumi Science 251, 350-353 (1953)). However this process is num Salt With a magnesium component such as magnesium obviously unpractical for industrial scale production of Salt in an aqueous medium in the presence of carbonate hydrotalcite, because the reaction system must be main ion at a pH of at least 8 and thereafter recovering the 20 tained under considerably high pressures.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]